- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
This study is testing a new medicine, TAK-861, for people with narcolepsy and cataplexy. Researchers want to see if it helps reduce sleepiness and cataplexy attacks, and if it's safe to use. It's a key step before the medicine could become widely available.
For: Narcolepsy with Cataplexy (Narcolepsy Type 1)Norway · Spain · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
This study is testing a new medicine, TAK-861, for people with narcolepsy type 1. Researchers want to see if it helps reduce symptoms like extreme sleepiness and sudden muscle weakness (cataplexy), and if it's safe to use. It's a key stage of testing before new medicines can be approved.
For: Narcolepsy with Cataplexy (Narcolepsy Type 1)Denmark · Finland · France - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Open-label single dose trial to evaluate pharmacokinetics, safety, and acceptability/palatability of oveporexton in children from 6 years to less than 18 years of age with narcolepsy type 1 (NT1)
This study looks at a new medicine called oveporexton for children aged 6 to 18 with narcolepsy type 1. It checks how the body handles the medicine, if it's safe, and if children find it easy to take and tasty.
For: Narcolepsy with Cataplexy (Narcolepsy Type 1)Italy